paracetduo 500 mg / 65 mg poretabletti
karo pharma as - paracetamolum,kofeiini - poretabletti - 500 mg / 65 mg - parasetamoli, yhdistelmävalmisteet
clariscan 0.5 mmol/ml injektioneste, liuos
ge healthcare as - gadoteric acid - injektioneste, liuos - 0.5 mmol/ml - gadoteerihappo
clariscan 0.5 mmol/ml injektioneste, liuos, esitäytetty ruisku
ge healthcare as - gadoteric acid - injektioneste, liuos, esitäytetty ruisku - 0.5 mmol/ml - gadoteerihappo
ventizolve 1.26 mg nenäsumute, liuos, kerta-annospakkaus
dne pharma as - naloxone hydrochloride dihydrate - nenäsumute, liuos, kerta-annospakkaus - 1.26 mg - naloksoni
camasan vet 380/60/50 mg/ml infuusioneste, liuos
interchemie werken de adelaar eesti as - boric acid, calcium gluconate ad iniectabile, magnesium chloride hexahydrate - infuusioneste, liuos - 380/60/50 mg/ml - kalsiumin yhdistelmävalmisteet d-vitamiinin ja/tai muiden lääkeaineiden kanssa
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - niveltulehdus, nivelreuma - immunosuppressantit - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
lumeblue (previously known as methylthioninium chloride cosmo)
alfasigma s.p.a. - metyylitioniniumkloridia - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.
sefazin vet 20 mg/ml injektioneste, liuos
interchemie werken de adelaar eesti as - xylazine hydrochloride - injektioneste, liuos - 20 mg/ml - ksylatsiini
sitagliptin/metformin grindeks 50 mg / 1000 mg tabletti, kalvopäällysteinen
as grindeks (jsc grindeks) - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 1000 mg - metformiini ja sitagliptiini
sitagliptin/metformin grindeks 50 mg / 850 mg tabletti, kalvopäällysteinen
as grindeks (jsc grindeks) - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 850 mg - metformiini ja sitagliptiini